Ovarian Granulosa Cell Tumor
Associated Genetic Biomarkers
NCI Definition: A granulosa-stromal cell tumor that arises from the ovary. It is characterized by the presence of granulosa cells that comprise at least ten percent of the cellular population. The granulosa cells are often found in a background that contains theca and fibrous cells. There are two major subtypes recognized, adult and juvenile granulosa cell tumor. Clinically, patients may present with an abdominal mass. Symptoms depend on the patient's age. The most important indicator of prognosis is tumor stage. Age over forty years at the time of the initial diagnosis, large tumor size, bilaterality, cellular atypia, and increased mitotic activity are factors indicating a potentially aggressive clinical course and relative poor prognosis. 
Ovarian granulosa cell tumors most frequently harbor alterations in FOXL2, KMT2D, PRKDC, TP53, and RUNX1 .
FOXL2 Mutation, FOXL2 C134W, KMT2fs, KMT2D Mutation, and PRKDC Mutation are the most common alterations in ovarian granulosa cell tumor .
There are 2 clinical trials for ovarian granulosa cell tumor, of which 2 are open and 0 are completed or closed. Of the trials that contain ovarian granulosa cell tumor as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
HLA-A*02:01 and PR are the most frequent gene inclusion criteria for ovarian granulosa cell tumor clinical trials .
Aldesleukin, cyclophosphamide, and decitabine are the most common interventions in ovarian granulosa cell tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.